Income during the third quarter increased to Rs 5,682.37 crore, from Rs 3,592.04 crore in the year-ago period
Given the dumping that is happening, the company is working towards increasing its share of exports to 30%-35%
NCLT yet to approve process; company filed first motion petition with tribunal nearly two years ago
Rating agency's report highlighting reasons for upgrade pointed at the improvement in financial risk profile, supported by debt reduction
Supriya Lifescience IPO seems to be reasonably priced, read detailed analysis